Mycoplasma pneumonia

Mycoplasma pneumoniae pneumonia (MPP) is a form of bacterial pneumonia caused by the bacterium Mycoplasma pneumoniae, representing a significant cause of community-acquired pneumonia in children and adolescents ^[1][2]. The infection typically presents with intermittent irritating cough accompanied by headache, fever, and muscle pain ^[2].

Clinical manifestations range from mild upper respiratory symptoms to severe pneumonia. Common symptoms include sore throat, wheezing, coughing, fever, headache, rhinitis, myalgia, and feelings of unease ^[1]. Primary atypical pneumonia represents the most severe manifestation, while tracheobronchitis is the most common presentation. Symptomatic infections develop gradually over several days and can be confused with other bacterial pathogens causing pneumonia. Rare severe outcomes include death from epithelial lesions, pulmonary edema, and bronchiolitis obliterans. Non-pulmonary complications occur in up to 25% of cases and may include autoimmune responses, central nervous system complications, dermatological disorders, hemolysis, carditis, joint disease, and gastrointestinal disease ^[1]. In some cases, infection can develop into refractory Mycoplasma pneumoniae pneumonia (RMPP), with elevated CRP, LDH, neutrophils, D-dimer, and lung consolidation serving as predictive factors ^[3].

Mycoplasma pneumoniae accounts for approximately 40% of community-acquired pneumonia cases, with children and elderly individuals being most susceptible ^[1]. The prevalence is greater among children than adults, as many adults remain asymptomatic while children typically develop symptoms ^[1]. Although incidence does not appear related to season or geography, infection tends to occur more frequently during summer and fall months when other respiratory pathogens are less prevalent. Reinfection and epidemic cycling are thought to result from P1 adhesin subtype variation ^[1]. No personal risk factors for acquiring M. pneumoniae have been identified ^[1].

Mycoplasma pneumoniae is spread through respiratory droplet and aerosol transmission ^[1]. Transmission is difficult to limit due to the several-day period of infection before symptoms appear ^[1].

Prevention measures are challenging due to the prolonged incubation period before symptom onset, which complicates early identification and isolation of cases. Cohorting patients has been found less effective because of this long incubation period. Network theory analyses suggest that limiting caregiver-patient interactions and reducing the movement of caregivers across multiple hospital wards represent the most effective prevention strategies ^[1]. As with other airborne pathogens, standard infection control precautions apply ^[1]. A safe and effective vaccine remains needed to provide protective immunity and reduce MPP incidence ^[2].

1. 1Wikipedia contributors. Mycoplasma pneumonia - Wikipedia [Internet]. Wikipedia. cited 3 Sept 2026.Available from: https://en.wikipedia.org/wiki/Mycoplasma_pneumonia
2. 2Gao L et al. Laboratory diagnosis and treatment of Mycoplasma pneumoniae infection in children: a review. Ann Med. 2024 Dec. PMID: 39097794. doi: 10.1080/07853890.2024.2386636.PubMed: https://pubmed.ncbi.nlm.nih.gov/39097794/
3. 3Huang W et al. Refractory Mycoplasma Pneumonia in Children: A Systematic Review and Meta-analysis of Laboratory Features and Predictors. J Immunol Res. 2022. PMID: 35795531. doi: 10.1155/2022/9227838.PubMed: https://pubmed.ncbi.nlm.nih.gov/35795531/